5

CLAIMS

- 1. A process for manufacturing a fibrin membrane, characterized in that it comprises the steps of:
- a) adding a physiological coagulating agent to blood plasma, up to gelling and clot formation;
 - b) removing the transudate from said blood clot by means of physiologic absorbent agents;
 - c) washing said blood clot with dehydrating and softening agents;
 - d) drying and sterilizing said dehydrated blood clot.
- 10 2. The process according to claim 1, characterized in that said physiological clotting agent is calcium chloride.
 - 3. The process according to claim 1 or 2, characterized in that said physiological absorbent agents are inorganic salts.
- 4. The process according to claim 3, characterized in that said inorganic salts are NaCl, NaHCO₃, or a mixture thereof.
 - 5. The process according to one of the previous claims, characterized in that said softening agents are low-boiling alcohols in propane-triol, in particular ethanol in propane-triol.
- 6. A fibrin membrane, characterized in that it is obtained by a process according to one or more previous claims.
 - 7. The fibrin membrane according to claim 6, characterized in that it shows a modulus of elasticity between 0.070 and 2.600 N/mm.
 - 8. The fibrin membrane according to claim 6 or 7, characterized in that it shows a breaking limit between 0.030 and 0.350 N/mm.
- 25 9. The fibrin membrane according to one or more claims from 6 to 8, characterized in that it shows a proportionality limit tension/strain between 0.025 and 0.085 N/mm.
 - 10. The fibrin membrane according to one or more claims from 6 to 9, characterized in that it is soaked with disinfectant agents.
- 30 11. The fibrin membrane according to one or more claims from 6 to 10, characterized in that it is soaked with drugs.

WO 2004/048449 PCT/IT2003/000780

- 11 -

12. The fibrin membrane according to one or more claims from 6 to 11, characterized in that it is soaked with tissue growth factors.